Cancer Risk(NYCBS)NCT07543159
Clinical Biospecimen Collection
An observational study of Cancer Risk, run by North Shore Hematology Oncology Associates P.C dba New York Cancer and Blood Specialists at 1 site in United States.
Trial summary
New York Cancer and Blood Specialists(NYCBS) is dedicated to provide world-class, patient-centered, affordable care to patients with cancer and blood disorders in their own communities, close to family and friends. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cancer Risk
- How many people
- 900,000 participants
- Where
- 1 siteUnited States
- Study dates
- 23 Dec 2025to 6 Oct 2035
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Subjects diagnosed with or suspected of having cancerous disease, or from healthy, normal donors with the goal of aiding in biomarker research, early detection of disease, and development of new devices or therapies.
Who may be able to join
- Subjects must be at least 18 years of age
- Subjects must be deemed competent by a qualified clinical study researcher to provide legally documented informed consent
- Subjects may or may not have active disease at the time of enrollment
- Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.
Who cannot join
- 4) Subjects not meeting the inclusion criteria
- Additional inclusion and exclusion criteria may exist, specific to individual project plans, for each collection falling under this protocol. These criteria may include genetic mutation status, progression of disease, and prior lines of therapy among others.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
NYCBS
Shirley, New York, 11967
Andrew Lee, MHA, andrew.lee@nycancer.com
About this study
Official title: New York Cancer and Blood Specialists: Clinical Biospecimen Collection for Research Use
New York Cancer and Blood Specialists(NYCBS) is dedicated to provide world-class, patient-centered, affordable care to patients with cancer and blood disorders in their own communities, close to family and friends. Our vision is a world free of cancer and blood disorders by contributing to the search for cures by offering cutting-edge clinical trials and personalized, state-of-the-art treatments that save and prolong lives. In support of these objectives NYCBS has created a centralized oncology biorepository in tandem with a longitudinal study to support translational research. This study establishes a biological sample bank and associated data reservoir from thousands of cancer patients, high risk populations, and survivors. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. Researchers will then use these samples and information to better understand how cancer affects the body over time in order to formulate new treatments. The information and samples provided will allow the testing of new therapies and aid in the development of new medical treatments.
Read the detailed description
Research and development of new diagnostics for earlier detection of, and new treatments for diseases require the use of human biological specimens (biospecimens). Through data and insight gained from the evaluation of these collected biospecimens, the aforementioned novel diagnostics and/or treatments can be developed or validated for a variety of diseases. Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.
The samples and data may be used for genetic research such as: RNA or DNA isolation and analysis, gene and protein expression, diagnostic device and biomarker research, tissue microarray development, laboratory tests and validation tests. The biospecimens may also be used for genome sequencing.
- Conditions
- Cancer Risk
- Keywords
- New York Cancer, Oncology, Cancer, Clinical Trial, Biobank, Umbrella
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Development of Assays, or Novel Diagnostic's and Treatments to Improve the Quality/Quantity of life for diseased individuals.
Expedite development of diagnostic assays and/or novel treatments to improve the quality and/or quantity of life for diseased individuals. Samples may also be utilized in the development of commercial diagnostic reagents." Reagents such as RNA, DNA, and proteins may be involved. Use of this genetic information may aid in the development of novel diagnostics and therapies for patients with certain diseases.
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Apr 2026
- Study start23 Dec 2025
- Primary completion6 Oct 2035 (estimated)
- Study completion6 Oct 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer RiskStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 900,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- North Shore Hematology Oncology Associates P.C dba New York Cancer and Blood Specialists
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Harry Staszewski, NY Health d/b/a New York Cancer and Blood Specialists
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07543159
- Sponsor's protocol ID
- WCG Protocol #20253750
- Acronym
- (NYCBS)
- Status last verified
- Oct 2025
- First submitted
- 15 Apr 2026
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- New York Cancer and Blood Specialists: Clinical Biospecimen Collection for Research Use
- ClinicalTrials.gov ID
- NCT07543159
- Acronym / sponsor ID
- (NYCBS) / WCG Protocol #20253750
- Conditions
- Cancer Risk
- Keywords
- New York Cancer, Oncology, Cancer, Clinical Trial, Biobank, Umbrella
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 900,000 participants (estimated)
- Lead sponsor
- North Shore Hematology Oncology Associates P.C dba New York Cancer and Blood SpecialistsUniversity, hospital or other
- Study start
- 23 Dec 2025 (actual)
- Primary completion
- 6 Oct 2035 (estimated)
- Study completion
- 6 Oct 2035 (estimated)
- First posted
- 21 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
New York Cancer and Blood Specialists(NYCBS) is dedicated to provide world-class, patient-centered, affordable care to patients with cancer and blood disorders in their own communities, close to family and friends. Our vision is a world free of cancer and blood disorders by contributing to the search for cures by offering cutting-edge clinical trials and personalized, state-of-the-art treatments that save and prolong lives. In support of these objectives NYCBS has created a centralized oncology biorepository in tandem with a longitudinal study to support translational research. This study establishes a biological sample bank and associated data reservoir from thousands of cancer patients, high risk populations, and survivors. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. Researchers will then use these samples and information to better understand how cancer affects the body over time in order to formulate new treatments. The information and samples provided will allow the testing of new therapies and aid in the development of new medical treatments.
Detailed description
Research and development of new diagnostics for earlier detection of, and new treatments for diseases require the use of human biological specimens (biospecimens). Through data and insight gained from the evaluation of these collected biospecimens, the aforementioned novel diagnostics and/or treatments can be developed or validated for a variety of diseases. Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.
The samples and data may be used for genetic research such as: RNA or DNA isolation and analysis, gene and protein expression, diagnostic device and biomarker research, tissue microarray development, laboratory tests and validation tests. The biospecimens may also be used for genome sequencing.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects diagnosed with or suspected of having cancerous disease, or from healthy, normal donors with the goal of aiding in biomarker research, early detection of disease, and development of new devices or therapies.
Key inclusion criteria (4 listed)
- Subjects must be at least 18 years of age
- Subjects must be deemed competent by a qualified clinical study researcher to provide legally documented informed consent
- Subjects may or may not have active disease at the time of enrollment
- Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.
Key exclusion criteria (2 listed)
- 4) Subjects not meeting the inclusion criteria
- Additional inclusion and exclusion criteria may exist, specific to individual project plans, for each collection falling under this protocol. These criteria may include genetic mutation status, progression of disease, and prior lines of therapy among others.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Development of Assays, or Novel Diagnostic's and Treatments to Improve the Quality/Quantity of life for diseased individuals.
Time frame: 10 years
Expedite development of diagnostic assays and/or novel treatments to improve the quality and/or quantity of life for diseased individuals. Samples may also be utilized in the development of commercial diagnostic reagents." Reagents such as RNA, DNA, and proteins may be involved. Use of this genetic information may aid in the development of novel diagnostics and therapies for patients with certain diseases.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Cancer Risk
RecruitingPhase 3
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia
Active, not recruitingPhase 3
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
Stage II Prostate Adenocarcinoma AJCC v7
RecruitingPhase 2
CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma
RecruitingObservational study
Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy
Brain Metastases, Bone Metastases
RecruitingObservational study
The French Gut-colo
Patients Aged 50-75 and Requiring Colonoscopy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer Risk, run by North Shore Hematology Oncology Associates P.C dba New York Cancer and Blood Specialists at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andrew Lee, MHA (16313935767, Biobanking@nycancer.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Development of Assays, or Novel Diagnostic's and Treatments to Improve the Quality/Quantity of life for diseased individuals. (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026; AzTrials last refreshed its copy on 30 Oct 2026.